Bio

As the former Executive Director of the Infectious Disease Research Center at Colorado State University from 2016 to 2023, I served as the primary contact for all external and internal partners in infectious disease research and was responsible for managing relationships with external laboratories. In this role, my duties included overall strategic responsibility for the IDRC and coordination of development and enhancement of infectious disease research and start-up companies and oversight of BioMARC, an FDA-inspected bio-manufacturing facility. My role focused on lowering translational barriers for CSU researchers as well as managing the financial aspects, teaching and training for faculty in the IDRC.

Co-Founder of MOLA Biotechnologies, a biotechnology company focused on developing new photochemical methods for treating blood products to prevent transfusion transmitted diseases.

Co-Founder of PhotonPharma, Inc., a biotechnology company focused on developing new cancer immunotherapy products.

President of Innovata BioConsulting. Providing consultation related to medical products with a focus on translational research, product development and product registration programs.

Former Vice President of Scientific and Clinical Affairs and Chief Science Officer/Blood Bank Technologies, for Terumo BCT transfusion medicine business.

Former Vice President/Chief Science Officer for CaridianBCT Biotechnologies, a division of CaridianBCT and formerly known as Navigant Biotechnologies.

Founder of Navigant Biotechnologies and CryoPharm Corporation. Inventor of the Mirasol PRT technology platform for blood banking and transfusion medicine.

I worked in the medical industry for 29 years during which I have managed technical staff and development programs in the fields of blood preservation, processing and pathogen reduction technologies. I am an active member of several professional organizations including the American Chemical Society, the Association for the Advancement of Blood and Biotherapies.   I have also held a position as an Adjunct Professor of Chemistry at The Ohio State University since 2005.

Research Overview

My research program is focused on using new methods to stimulate immune response in patients with cancer and as a means to prevent infectious diseases. The first clinical application of new technology developed in my lab is for treatment of patients with advanced stage ovarian cancer (Innocell™). In addition, my group is focused on developing methods to generate new vaccine candidates for infectious diseases in humans and animals. Our current program of work includes research on new vaccine formulations for SARS-CoV-2, Tuberculosis, Influenza and African Swine Fever, using a technology platform for production of vaccines.

My work has also focused on the use of photochemical methods to treat blood products for the prevention of transfusion transmitted diseases.  I am an inventor of the Mirasol PRT technologies which has been in routine use since 2007 in the blood banking and transfusion and transplantation medicine sector and have recently been engaged in research to create a next generation device and disposable for delivering pathogen inactivated blood products.

Publications 

I have authored over 200 peer reviewed publications.  A full listing of my bibliography is available at the following links:

Google Scholar for Raymond Goodrich

NCBI Bibliography for Raymond Goodrich

ORCID iD for Raymond Goodrich

Most recent publications include the following:

1.        Dose-Dependent Efficacy of a Riboflavin and Ultraviolet Light-Inactivated Whole-Virion SARS-CoV-2 Vaccine in a Hamster Infection Challenge Model.

Altina N, Ragan IK, Arnett KA, Jones S, Glass A, Dutt TS, Obregon-Henao A, Maldonado P, Harris M, Bowen RA, Kruh-Garcia N, Heaslip D, Yonemura S, Henao-Tamayo M, Goodrich RP. Vaccines (Basel). 2026 Jan 27;14(2):121. doi: 10.3390/vaccines14020121. PMID: 41746044; PMCID: PMC12945153.

2.        Kaposi’s sarcoma herpesvirus seroprevalence among blood donors in Uganda

Huso T, White JL, Kyeyune D, D’Adamo A, Labo N, Miley W, et al. Transfusion. 2025. https://doi.org/10.1111/trf.18236

3.        Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies

Cardoso M, Ragan I, Hartson L, Goodrich RP. Pathogens. 2023 Jul 5;12(7):911. doi: 10.3390/pathogens12070911. PMID: 37513758

4.        SARS-CoV-2 seroprevalence among blood donors in Uganda: 2019-2022.

Bloch EM, Kyeyune D, White JL, Ddungu H, Ashokkumar S, Habtehyimer F, Baker O, Kasirye R, Patel EU, Grabowski MK, Musisi E, Moses K, Hume HA, Lubega I, Shrestha R, Motevalli M, Fernandez RE, Reynolds SJ, Redd AD, Wambongo Musana H, Dhabangi A, Ouma J, Eroju P, de Lange T, Fowler MG, Musoke P, Stramer SL, Whitby D, Zimmerman PA, McCullough J, Sachithanandham J, Pekosz A, Goodrich R, Quinn TC, Ness PM, Laeyendecker O, Tobian AAR. Transfusion. 2023 Jul;63(7):1354-1365. doi: 10.1111/trf.17449. Epub 2023 Jun 16. PMID: 37255467

5.        Pathogen reduction of monkeypox virus in plasma and whole blood using riboflavin and UV light.

Izabela K Ragan, Lindsay M Hartson, Elizabeth J Sullivan, Richard A Bowen, Raymond P Goodrich (2023) PLoS One 18 (1), e0278862